Take a look at some of Monday's midday movers:
Achillion Pharmaceuticals - The drug maker rallied after Maxim Group raised its price target to $22 from $6 and maintained its buy rating.
Biogen Idec - The drug maker edged lower as did those of AbbVie after the companies disclosed partial but mixed results from a drug trial involving patients with relapsing-remitting multiple sclerosis.
DreamWorks Animation SKG - The studio fell after box office receipts for its "Dragon 2" movie came in short of expectations.
Exelon - The utility rose along with others in its sector, including Ameren, Edison International and CenterPoint Energy.
General Electric - The infrastructure and financial services company fell after Germany's Siemens and Japan's Mitsubishi Heavy Industries made a joint offer to France's Alstom for some of its assets, challenging a bid by GE.
Lithia Motors - The retailer of new and used vehicles rose after it agreed to buy DCH Auto Group for $362.5 million, giving it a foothold in the eastern United States.
Medtronic - The medical device maker declined after executives at the company told a conference call it would stay in the market for new technologies even as it digests Dublin-based medical device maker Covidien. The $42.9 billion acquisition announced on Sunday help propel others in the space higher, including Boston Scientific, Stryker, St. Jude Medical and Intuitive Surgical.
Netflix - The online provider of television shows and films edged lower after it announced an animated series with toy and game maker Mattel.
New York Times - The publishing company edged higher after Executive Editor Dean Bacquet told staff in a memo that he had a malignant tumor on his kidney removed.
Starbucks - The coffee seller was mildly higher after partnering with Arizona State University to offer steep discounts for online degrees to 135,000 U.S. employees.
Tesla Motors - The electric car maker rose as investors cheered last week's decision by the company to share its technology patents.
(Read More: )
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at marketinsider@cnbc.com